Bird JA, et al. - AR101, a novel oral biologic drug product, was assessed for safety and efficacy in oral immunotherapy for peanut allergy in this first phase 2 multicentered study conducted at 8 US centers. With an acceptable safety profile, AR101 displayed clinical activity indicative of its potential as an immunomodulatory treatment option in peanut-allergic children over the age of 4, adolescents, and young adults.